Interaksi Lisinopril

Lisinopril (Zestril, Prinivil, Qbrelis), golongan penghambat ACE, memiliki 252 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 26 mayor, 179 moderat, 47 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Lisinopril adalah penghambat ACE yang dijual sebagai Zestril, Prinivil, dan Qbrelis, serta secara luas sebagai obat generik. Obat ini melemaskan dan melebarkan pembuluh darah, yang menurunkan tekanan darah dan meringankan beban kerja jantung. Obat ini disetujui untuk tekanan darah tinggi pada orang dewasa dan anak berusia 6 tahun ke atas, sebagai terapi tambahan pada gagal jantung, dan untuk memperbaiki kelangsungan hidup setelah serangan jantung. Obat ini tersedia sebagai tablet atau cairan oral dan biasanya diminum sekali sehari, dengan atau tanpa makanan.

Interaksi dari label

Interaksi mayor (26)

  • AliskirenantihipertensiMayor

    Zestril is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema Do not co-administer aliskiren with ZESTRIL in patients with diabetes [see Drug Interactions (7.4) ] . (label Lisinopril, Kontraindikasi)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinMayor

    Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [ see Warnings and Precautions (5.2)] . (label Lisinopril, Kontraindikasi)

  • Benazeprilpenghambat ACEMayor

    CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (label Benazepril, Kontraindikasi)

  • Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (label Benazepril dan hidroklorotiazid, Kontraindikasi)

  • EptifibatidantiplateletMayor

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (label Eptifibatid, Kontraindikasi)

  • EverolimusimunosupresanMayor

    Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (label Everolimus, Interaksi obat)

  • Fosinoprilpenghambat ACEMayor

    CONTRAINDICATIONS Fosinopril sodium tablets are contraindicated in patients who are hypersensitive to this product or to any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema with any other ACE inhibitor therapy). (label Fosinopril, Kontraindikasi)

  • Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (label Fosinopril dan hidroklorotiazid, Kontraindikasi)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. (label Irbesartan dan hidroklorotiazid, Peringatan dan perhatian)

  • KaliumVitamin dan mineralMayor

    Obat-obat ini mengurangi ekskresi kalium; menambahkan suplemen kalium atau garam pengganti dapat menyebabkan hiperkalemia, yang memengaruhi irama jantung. (NIH Office of Dietary Supplements, Potassium)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Mayor

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (label Kandesartan, Interaksi obat)

  • Kaptoprilpenghambat ACEMayor

    CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (label Kaptopril, Kontraindikasi)

  • KlozapinantipsikotikMayor

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (label Klozapin, Peringatan kotak hitam)

  • Losartanpenghambat reseptor angiotensin II (ARB)Mayor

    Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (label Lisinopril, Interaksi obat)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (label Lisinopril, Interaksi obat)

  • Metolazondiuretik tiazidMayor

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (label Metolazon, Peringatan)

  • MinoksidilvasodilatorMayor

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (label Minoksidil, Peringatan kotak hitam)

  • Perindoprilpenghambat ACEMayor

    Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. (label Perindopril, Kontraindikasi)

  • Ramiprilpenghambat ACEMayor

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (label Ramipril, Kontraindikasi)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Mayor

    Zestril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (label Lisinopril, Kontraindikasi)

  • Tadalafilpenghambat PDE5Mayor

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (label Tadalafil, Peringatan dan perhatian)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker ( 5.6 ) (label Telmisartan, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Mayor

    Avoid concomitant use with an ACE inhibitor (5.6) (label Telmisartan dan amlodipin, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Patients who received the combination of ARB and ACE inhibitor did not obtain any additional benefit (no additional reduction of risk of cardiovascular death, myocardial infarction, stroke, or hospitalization from heart failure) compared to ARB monotherapy or ACE inhibitor monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal… (label Telmisartan dan hidroklorotiazid, Interaksi obat)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Mayor

    Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [ see Warnings and Precautions (5.2)] . (label Lisinopril, Kontraindikasi)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Mayor

    Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [ see Warnings and Precautions (5.2)] . (label Lisinopril, Kontraindikasi)

Interaksi moderat (179)

  • AkarbosaantidiabetesModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Alfuzosinpenyekat alfaModerat

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (label Alfuzosin, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • AlteplaseModerat

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (label Alteplase, Interaksi obat)

  • Amiloriddiuretik hemat kaliumModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Lisinopril, Interaksi obat)

  • AripiprazolantipsikotikModerat

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (label Aripiprazol, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (label Armodafinil, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Asam mefenamatOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • AsenapinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Asenapin, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • AspirinOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Aspirin dan dipiridamolantiplateletModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Atenololpenyekat betaModerat

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Atenolol, Peringatan)

  • Atenolol dan klortalidonpenyekat betaModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Atomoksetinpenghambat ambilan kembali norepinefrinModerat

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (label Atomoksetin, Interaksi obat)

  • Avanafilpenghambat PDE5Moderat

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (label Avanafil, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Lisinopril, Interaksi obat)

  • Beksagliflozinpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Benzfetaminstimulan SSPModerat

    Amphetamines may decrease the hypotensive effect of antihypertensives. (label Benzfetamin, Interaksi obat)

  • Bisoprololpenyekat betaModerat

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol, Peringatan)

  • Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • BortezomibModerat

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (label Bortezomib, Peringatan dan perhatian)

  • BrekspiprazolantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Brekspiprazol, Peringatan dan perhatian)

  • Brimonidinagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (label Brimonidin, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (label Brimonidin dan timolol, Interaksi obat)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (label Bromfeniramin, pseudoefedrin, dan dekstrometorfan, Interaksi obat)

  • Bromokriptinagonis dopaminModerat

    Use caution in patients taking antihypertensive medications. (label Bromokriptin, Peringatan dan perhatian)

  • Bumetaniddiuretik loopModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Dalfampridinsuplemen kaliumModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • Dapagliflozinpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Deksmetilfenidatstimulan SSPModerat

    • Antihypertensive Drugs: Monitor blood pressure. (label Deksmetilfenidat, Interaksi obat)

  • Dietilpropionstimulan SSPModerat

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (label Dietilpropion, Interaksi obat)

  • DiflunisalOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • DiklofenakOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • DofetilidantiaritmiaModerat

    Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (label Dofetilid, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • DuloksetinSNRIModerat

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (label Duloksetin, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Empagliflozinpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (label Epinefrin, Interaksi obat)

  • Eplerenonantagonis aldosteronModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (label Epoetin alfa, Peringatan dan perhatian)

  • Epoprostenolanalog prostaglandinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Esmololpenyekat betaModerat

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (label Esmolol, Interaksi obat)

  • EtodolakOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Fenelzinpenghambat MAOModerat

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (label Fenelzin, Peringatan)

  • FenilefrindekongestanModerat

    Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (label Fenilefrin, Interaksi obat)

  • FenoprofenOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • FlurbiprofenOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Furosemiddiuretik loopModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • GlibenklamidsulfonilureaModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Glibenklamid dan metforminsulfonilureaModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • GlimepiridsulfonilureaModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • GlipizidsulfonilureaModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Hidroklorotiaziddiuretik tiazidModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • IbuprofenOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • IloperidonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Iloperidon, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • IndometasinOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Insulin aspartinsulinModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Insulin degludekinsulinModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Insulin detemirinsulinModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Insulin glargininsulinModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Insulin lisproinsulinModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Lisinopril, Interaksi obat)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (label Kalium iodida, Interaksi obat)

  • Kalium kloridasuplemen kaliumModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • Kalium sitratsuplemen kaliumModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • KarbidopaModerat

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (label Karbidopa, Interaksi obat)

  • Karbidopa dan levodopaobat dopaminergikModerat

    Antihypertensive drugs: May cause symptomatic postural hypotension. (label Karbidopa dan levodopa, Interaksi obat)

  • Karbidopa, levodopa, dan entakaponobat dopaminergikModerat

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

  • KariprazinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Kariprazin, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (label Karvedilol, Peringatan dan perhatian)

  • KetoprofenOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • KetorolakOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Klorotiaziddiuretik tiazidModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • KuetiapinantipsikotikModerat

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Kuetiapin, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    As with other ACE inhibitors, periodic monitoring of white blood cell counts in patients with collagen vascular disease and/or renal disease should be considered. (label Kuinapril, Peringatan)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Lantanumpengikat fosfatModerat

    Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (label Lantanum, Interaksi obat)

  • Linagliptinpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Liraglutidagonis reseptor GLP-1Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Litiumobat serotonergikModerat

    Lithium: Symptoms of lithium toxicity ( 7.5 ) (label Lisinopril, Interaksi obat)

  • LumateperonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Lumateperon, Peringatan dan perhatian)

  • LurasidonantipsikotikModerat

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (label Lurasidon, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (label Mekamilamin, Interaksi obat)

  • MeloksikamOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • MetforminbiguanidModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Metilfenidatstimulan SSPModerat

    Antihypertensive Drugs: Monitor blood pressure. (label Metilfenidat, Interaksi obat)

  • Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • MiglitolantidiabetesModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • MirtazapinantidepresanModerat

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (label Mirtazapin, Peringatan dan perhatian)

  • Modafinilstimulan SSPModerat

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (label Modafinil, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Hypotension Moexipril hydrochloride can cause symptomatic hypotension, although, as with other ACE inhibitors, this is unusual in uncomplicated hypertensive patients treated with moexipril hydrochloride alone. (label Moeksipril, Peringatan)

  • NabumetonOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NaproksenOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NateglinidmeglitinidModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • Natrium polistiren sulfonatsuplemen kaliumModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • NiasinModerat

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (label Niasin, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. (label Nifedipin, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (label Nimodipin, Interaksi obat)

  • NitrogliserinnitratModerat

    Antihypertensives: Possible additive hypotensive effects. (label Nitrogliserin, Interaksi obat)

  • OksaprozinOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • OktreotidModerat

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (label Oktreotid, Interaksi obat)

  • OlanzapinantipsikotikModerat

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (label Olanzapin, Peringatan dan perhatian)

  • Olanzapin dan fluoksetinantipsikotikModerat

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Lisinopril, Interaksi obat)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • PaliperidonantipsikotikModerat

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (label Paliperidon, Peringatan dan perhatian)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • PazopanibModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • PentoksifilinmetilxantinModerat

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (label Pentoksifilin, Interaksi obat)

  • PioglitazontiazolidindionModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Pioglitazon dan metformintiazolidindionModerat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • PiroksikamOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Prazosinpenyekat alfaModerat

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (label Prazosin, Peringatan)

  • PregabalinantikonvulsanModerat

    In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema. (label Pregabalin, Peringatan dan perhatian)

  • RepaglinidmeglitinidModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

  • RiosiguatvasodilatorModerat

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (label Riosiguat, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (label Risperidon, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • SalsalatOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • SelekoksibOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • Semaglutidagonis reseptor GLP-1Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Siklobenzaprinpelemas ototModerat

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (label Siklobenzaprin, Interaksi obat)

  • SiklofosfamidimunosupresanModerat

    Table 2: Drugs that Potentiate Cyclophosphamide Toxicities Toxicity Drugs Increased hematotoxicity and/or immunosuppression ● ACE inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity… (label Siklofosfamid, Interaksi obat)

  • SiklosporinimunosupresanModerat

    Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (label Siklosporin, Interaksi obat)

  • Sildenafilpenghambat PDE5Moderat

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (label Sildenafil, Peringatan dan perhatian)

  • Silodosinpenyekat alfaModerat

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (label Silodosin, Peringatan dan perhatian)

  • SirolimusimunosupresanModerat

    Angioedema and Anaphylactoid Reactions Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. [see Drug Interactions (7.7 , 7.8)] . (label Lisinopril, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • SorafenibModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor. (label Sulfametoksazol dan trimetoprim (kotrimoksazol), Interaksi obat)

  • SulindakOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • SunitinibModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (label Takrolimus, Peringatan dan perhatian)

  • Angioedema and Anaphylactoid Reactions Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. [see Drug Interactions (7.7 , 7.8)] . (label Lisinopril, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (label Terazosin, Peringatan dan perhatian)

  • TestosteronandrogenModerat

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (label Testosteron, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

  • TolmetinOAINSModerat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (label Lisinopril, Interaksi obat)

  • TolvaptanModerat

    Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (label Tolvaptan, Interaksi obat)

  • Torasemiddiuretik loopModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Like other ACE inhibitors, trandolapril has only rarely been associated with symptomatic hypotension in uncomplicated hypertensive patients. (label Trandolapril, Peringatan)

  • TrazodonantidepresanModerat

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (label Trazodon, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (label Vardenafil, Interaksi obat)

  • VenlafaksinSNRIModerat

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (label Verapamil, Interaksi obat)

  • ZiprasidonantipsikotikModerat

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Ziprasidon, Peringatan dan perhatian)

Penyebutan minor (47)

  • AzatioprinimunosupresanMinor

    Use with Angiotensin-Converting Enzyme Inhibitors: The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. (label Azatioprin, Interaksi obat)

  • AzelastinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • ButorfanolopioidMinor

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (label Butorfanol, Peringatan)

  • DeksklorfeniraminantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Dekstroamfetaminstimulan SSPMinor

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (label Dekstroamfetamin, Interaksi obat)

  • Desipraminantidepresan trisiklikMinor

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (label Desipramin, Peringatan)

  • DesloratadinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Desogestrel dan etinilestradiolkontrasepsi oralMinor

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (label Desogestrel dan etinilestradiol, Peringatan)

  • DifenhidraminantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • DimenhidrinatantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • DoksilaminantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Doksilamin dan piridoksinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • EfedrinsimpatomimetikMinor

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (label Efedrin, Interaksi obat)

  • Enalaprilatpenghambat ACEMinor

    Neutropenia/Agranulocytosis Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. (label Enalaprilat, Peringatan)

  • FeksofenadinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Finasteridpenghambat 5-alfa reduktaseMinor

    …specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory… (label Finasterid, Interaksi obat)

  • HidralazinvasodilatorMinor

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (label Hidralazin, Interaksi obat)

  • Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • HidroksizinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (label Ikatibant, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinMinor

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (label Isradipin, Interaksi obat)

  • KarbinoksaminantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • KlemastinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • KlorfeniraminantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • KlorpromazinantipsikotikMinor

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (label Klorpromazin, Peringatan)

  • LevosetirizinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • LoratadinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • MeklizinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • MeksiletinantiaritmiaMinor

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (label Meksiletin, Interaksi obat)

  • MetildopaantihipertensiMinor

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (label Metildopa, Interaksi obat)

  • Metoprololpenyekat betaMinor

    Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Metoprolol, Peringatan dan perhatian)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (label Natrium zirkonium siklosilikat, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinMinor

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (label Nisoldipin, Interaksi obat)

  • NitroprusidvasodilatorMinor

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (label Nitroprusid, Peringatan)

  • Nortriptilinantidepresan trisiklikMinor

    The antihypertensive action of guanethidine and similar agents may be blocked. (label Nortriptilin, Peringatan)

  • OlopatadinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • ProklorperazinantipsikotikMinor

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (label Proklorperazin, Perhatian)

  • PrometazinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • Protriptilinantidepresan trisiklikMinor

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (label Protriptilin, Peringatan)

  • SetirizinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • SidofovirantivirusMinor

    Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (label Sidofovir, Interaksi obat)

  • SiproheptadinantihistaminMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • TrifluoperazinantipsikotikMinor

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (label Trifluoperazin, Perhatian)

Periksa Lisinopril terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.